Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Blue Cross Blue Shield of Florida will begin covering the firm's ThyGenX and ThyraMir molecular thyroid tests.

The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used together to diagnose thyroid nodules with indeterminate cytology. The combination testing includes the rule-in properties of next-generation sequencing of a patient's DNA and RNA, and the rule-out capabilities of a miRNA classifier, according to Interpace.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.